IDH1 and hematologic disorder: Study of Orally Administered AG-120 (Ivosidenib) in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation————————————Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia